Table 1 Information on NHP studies sourced for this study43,44,45,46,47, including unpublished ongoing studies
Year study performed | Species and sample size | Age range (years) | Vaccine types | Administration route | Reference |
|---|---|---|---|---|---|
2016 | Indian Macaca mulatta, n = 24 (14 M + 10 F) | M: 2.7–4.2, F: 2.7–3.7 | Protein vaccine in adjuvant | s.c. or i.m. | Thompson et al.45 |
2017 | Indian Macaca mulatta, n = 14 (4 M + 10 F) | M: 4.0–4.3, F: 3.8–4.8 | Protein vaccine in adjuvant | i.m. | Ols et al.46 |
2018 | Chinese Macaca mulatta, n = 18 (9 M + 9 F) | M: 3.2–3.5, F: 3.1–3.5 | mRNA vaccine or inactivated virus vaccine | i.m. | Hellgren et al.43 |
2018 | Chinese Macaca mulatta, n = 18 (9 M + 9 F) | M: 3.4–3.7, F: 3.3–3.8 | mRNA vaccine | i.m. | Not yet published |
2020–2021 | Indian Macaca mulatta, n = 12 (6 M + 6 F) | M: 4.3–6.8, F: 4.4–6.3 | Protein vaccine in adjuvant | i.m. | Lenart et al.44 |
2020–2021 | Indian Macaca mulatta, n = 12 (9 M + 3 F) | M: 4.4–6.2, F: 5.1–5.2 | Peptides with anti-CD40 mAb | s.c. or i.v. | Yan et al.47 |
2023 | Indian Macaca mulatta, n = 15 (8 M + 7 F) | M: 7.4–9.3, F: 7.4–9.4 | mRNA vaccine | i.m. | Not yet published |
2023 | Macaca fascicularis, n = 20 (10 M + 10 F) | M: 4.2–4.5, F: 3.9–6.4 | Protein vaccine in adjuvant | i.m. | Not yet published |
2023 | Macaca fascicularis, n = 2 (2 F) | F: 11.5–16.8 | Peptides with anti-CD40 mAb | s.c. | Not yet published |
